Reversible Activation Defect of the Platelet Glycoprotein IIb-IIIa Complex in Patients With Uremia

Ariela Benigni; Paola Boccardo; Miriam Galbusera; Juan Manuel Monteagudo Ruiz; Luigi De Marco; Giuseppe Remuzzi; Z M Ruggeri

doi:10.1016/s0272-6386(12)80429-x

Related publications

Article2007

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes

Omar Dabbous, Frederick A. Anderson, Joel M. Gore, Kim A. Eagle, Keith A.A. Fox, Rajendra H. Mehta, Robert J. Goldberg, Giancarlo Agnelli, Philippe Gabríel Steg

Article2006

Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups

Adrían V. Hernández, Cynthia M. Westerhout, Ewout W. Steyerberg, John P A Ioannidis, Héctor Bueno, H. D. White, Pierre Théroux, David J. Moliterno, Paul W. Armstrong, Robert M. Califf, Lars Wallentin, M. L. Simoons, Eric Boersma

Article2003

Effect of intravenous glycoprotein IIb/IIIa receptor antagonists on survival in percutaneous coronary interventions: A meta-analysis

Evangelia Karvouni, Demosthenes G. Katritsis, John P A Ioannidis

Article2010

Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics

Timm Bauer, Helge Möllmann, Franz Weidinger, Uwe Zeymer, Ricardo Seabra‐Gomes, Franz R. Eberli, Patrick W. Serruys, Alec Vahanian, Sigmund Silber, William Wijns, Matthias Hochadel, Holger Nef, Christian W. Hamm, Jean Marco, Anselm K. Gitt

Clinical Research in Cardiology

Article1983

Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT

Giuseppe Remuzzi, Ariela Benigni, P. Dodesini, Arrigo Schieppati, M. Livio, Giovanni de Gaetano, Jeffrey S. Day, William L. Smith, E Pinca, Paola Patrignani, Carlo Patrono